Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 35
Filtrar
1.
Rev Gastroenterol Peru ; 41(1): 6-10, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34347763

RESUMEN

INTRODUCTION: Irritable bowel syndrome (IBS) is a chronic functional bowel condition with an average world prevalence of 11.2%. Is associated with multiple factors as female sex, young age, stress, anxiety and depression which can have a negative impact on quality of life. IBS in Peru is not investigated at all specially in the Andean region. The objective of this study is to determine the prevalence and associated factors of IBS in an Andean community from Peru using the Rome IV criteria. MATERIALS AND METHODS: Cross-sectional study in a rural community dedicated to livestock and agriculture in Peru at 3,235 meters above sea level. Questionnaires provided by the Rome Foundation as the Rome IV - Diagnostic questionnaire for adults, Irritable Bowel Syndrome - Symptom Severity Scale and Bristol stool scale were used. RESULTS: 130 residents met the inclusion criteria. 46.9% were males with an average age of 54 years old. 11.54% presented red flags and were not included in the analysis. 13.1% were diagnosed with IBS and 52.9% presented constipation as predominant bowel pattern. 52.9% presented a mild course of the disease. In the chi-square analysis, factors as depression, anxiety, female sex, younger age, liquefied petroleum gas exposure for cooking and education achievement were statistically significant associated to IBS. In the logistic regression analysis, anxiety was the unique independent predictor factor with an OR of 9.6 (95% IC: 1.78-51.82). CONCLUSION: IBS is a prevalent condition in the Andean region and should be managed as a public health issue to improve quality of life.


Asunto(s)
Síndrome del Colon Irritable , Adulto , Estreñimiento , Estudios Transversales , Femenino , Humanos , Síndrome del Colon Irritable/diagnóstico , Síndrome del Colon Irritable/epidemiología , Síndrome del Colon Irritable/etiología , Masculino , Persona de Mediana Edad , Perú/epidemiología , Calidad de Vida
2.
Rev Gastroenterol Peru ; 39(3): 284-287, 2019.
Artículo en Español | MEDLINE | ID: mdl-31688855

RESUMEN

Balantidiasis is a zoonosis produced by Balantidium coli, which inhabits the large intestine of the pig and man. Infection is uncommon in humans and mainly affects the colon. It occurs more frequently in developing countries, tropical and subtropical regions. Colonic balantidiasis can occur in most cases asymptomatically and reach in the most severe cases such as dysenteric diarrhea that can be complicated by low digestive bleeding and even perforation. We present the case of a 72-year-old man, from the Peruvian highlands, who was a farmer and breeder of swine and sheep, who came for 3 months of illness, initially characterized by liquid stools with bloodless mucus, abdominal pain, nausea, vomiting and in the last month of illness he presents dysenteric diarrhea. Colonoscopy was performed due to suspicion of infectious colitis, Balantidium coli trophozoites were found in the fresh sample and colonic tissue biopsy. Patient receives treatment with amebicide and antibacterial without clinical improvement, presenting as a complication multiple perforation in the sigmoid colon, treated with resection and terminal colostomy. Finally, the patient died despite receiving medical and surgical treatment.


Asunto(s)
Balantidiasis , Enfermedades del Colon/parasitología , Anciano , Balantidiasis/diagnóstico , Balantidiasis/terapia , Enfermedades del Colon/diagnóstico , Enfermedades del Colon/terapia , Resultado Fatal , Humanos , Masculino
3.
Rev Gastroenterol Peru ; 39(3): 229-238, 2019.
Artículo en Español | MEDLINE | ID: mdl-31688846

RESUMEN

In lower gastrointestinal bleeding (LGIB), it is very important to stratify the risk of LGIB for a proper management. OBJECTIVE: Identity the independent risk factors to mortality and severity (require critical care, prolonged hospitalization, reebleding, re hospitalization, politrasfusion, surgery for bleeding control) in LGIB. MATERIALS AND METHODS: It is an analytic prospective cohort study, performed between June 2016 and April 2018 in a tertiary care hospital. Independent factors were determined using binomial logistic regression. RESULTS: A total of 98 patients were included, of which 13 patients (13,3%) died, and 56 (57,1%) met severity criteria. The independent risk factor for mortality was Glasgow scale under 15, and for severe bleeding were: Systolic blood pressure under 100 mm Hg, albumin lower than 2,8 g/dL. CONCLUSIONS: The frequency of mortality and severe LGIB is high in our population, the principal risk factors were systolic blood pressure under than 100 mm Hg, Glasgow score lower than 15, albumin lower than 2,8 g/dL. Identifying these associated factors would improve the management of LGB in the emergency room.


Asunto(s)
Hemorragia Gastrointestinal/diagnóstico , Hemorragia Gastrointestinal/mortalidad , Enfermedades Intestinales/diagnóstico , Enfermedades Intestinales/mortalidad , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Medición de Riesgo , Factores de Riesgo , Índice de Severidad de la Enfermedad , Adulto Joven
4.
Rev Gastroenterol Peru ; 39(3): 246-251, 2019.
Artículo en Español | MEDLINE | ID: mdl-31688848

RESUMEN

OBJECTIVE: To evaluate the therapeutic success of endoscopic therapy with N-butyl-2-cyanoacrylate and to determine the re- bleeding and mortality rates. MATERIALS AND METHODS: Prospective analytical observational study of 47 cases of patients with gastric varices who were treated with N-butyl-2-cyanoacrylate, using a 1: 1 mixture with lipiodol between 2013 and 2017 in a level III public hospital in Lima - Peru. The therapeutic indication was active hemorrhage, primary or secondary prophylaxis. RESULTS: Of the 47 patients, 5 (10.6%) had active hemorrhage, control was obtained in all cases, 24 (51.1%) had stigmas of recent bleeding during endoscopy. Secondary prophylaxis was performed in 16 (34%) patients and primary prophylaxis in 2 (4.7%). 59.6% required a single session with a total volume of cyanoacrylate (ml / patient) of 1.28 ± 0.44. The endoscopic finding was GOV-2 in 78.7% of the cases, IGV-1 in 12.8% and GOV-1 in 8.5%. Seven patients (14.8%) presented late re- bleeding, with successful new therapy in 6 of them, one dying due to therapy failure. Of the six (12.76%) patients who died in total, 5 (83.3%) were due to other causes. No adverse events related to the therapy were reported. No adverse events were reported. Variceal obturation was observed in 28 (59.5%) patients. CONCLUSIONS: Endoscopic management of gastric varices with cyanoacrylate is a safe and effective treatment, with low recurrence and mortality rates.


Asunto(s)
Cianoacrilatos/uso terapéutico , Várices Esofágicas y Gástricas/tratamiento farmacológico , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Hospitales Públicos , Humanos , Masculino , Persona de Mediana Edad , Perú , Estudios Prospectivos , Salud Urbana , Adulto Joven
5.
Rev Gastroenterol Peru ; 38(1): 22-28, 2018.
Artículo en Español | MEDLINE | ID: mdl-29791417

RESUMEN

BACKGROUND: The predictors proposed by the American Society of Gastrointestinal Endoscopy (ASGE) are commonly used topredict the presence and management of choledocholithiasis. OBJECTIVE: To evaluate the performance and precision of thepredictors of choledocholithiasis proposed by ASGE. MATERIALS AND METHODS: Prospective and longitudinal study performed ata third level hospital during January 2015 to June 2017. All patients with high and intermediate probability of choledocholithiasiswho underwent endoscopic retrograde cholangiopancreatography (ERCP) were included according to the criteria proposedby the ASGE. RESULTS: A total of 246 patients with suspected choledocholithiasis were analyzed. Of the 228 patients withhigh probability criteria 144 (63.2% = performance) had choledocholithiasis in ERCP with an accuracy of 62% (sensitivity:94.1% and specificity: 9.7%). Among the 18 patients with intermediate probability criteria, 9 (50% = performance) hadcholedocholithiasis with an accuracy of 38% (sensitivity: 5.9% and specificity: 90.3%). In the multivariate analysis, the presenceof stone in the bile duct by ultrasonography (OR: 1.937, 95% CI 1.048-3.580, p=0.035) and age 55 and over (OR: 2.121, 95%CI, 1.101-4.088, p=0.025) were the strongest predictors for choledocholithiasis. CONCLUSIONS: The application of the criteriaof the ASGE to predict the probability of choledocholithiasis, in our population has a performance greater than 50%, however,it is necessary to improve these parameters to avoid an unnecessary performance of ERCP.


Asunto(s)
Coledocolitiasis/diagnóstico , Adulto , Anciano , Anciano de 80 o más Años , Colangiopancreatografia Retrógrada Endoscópica , Toma de Decisiones Clínicas , Endoscopía Gastrointestinal , Femenino , Hospitales Públicos , Humanos , Estudios Longitudinales , Masculino , Persona de Mediana Edad , Análisis Multivariante , Perú , Estudios Prospectivos , Sensibilidad y Especificidad , Sociedades Médicas , Ultrasonografía
6.
Rev Gastroenterol Peru ; 37(1): 53-57, 2017.
Artículo en Español | MEDLINE | ID: mdl-28489837

RESUMEN

OBJECTIVE: To validate a rapid urease test (RUT) in Cayetano Heredia Hospital (HCH) in Lima, Peru. MATERIALS AND METHODS: This is a prospective observational study that included 181 patients over 18 years old with dyspeptic symptoms. All of them underwent upper gastrointestinal endoscopy at the Department of Gastroenterology at HCH. They had not received, during the last four weeks, proton pump inhibitors (PPIs), bismuth or antibiotics. Two biopsies of antrum were taken, one to perform the TRU (Sensibacter pylori test®) and the other one for pathology, in order to determine by both methods the presence of H. pylori infection. TRU's results were compared with pathology ́s (gold standard). RESULTS: 181 patients, average age 52.8±13.5 years, were evaluated. The sensitivity, specificity, negative predictive value (NPV), positive predictive value (PPV) at 20 minutes were 86.8%, 98.5%, 81.5% and 99% and at 24 hours 97.3%, 99.5%, 95.7% y 99.1% respectively. CONCLUSION: The rapid urease test is a reliable, accessible and easy to apply test for the diagnosis of H. pylori infection.


Asunto(s)
Mucosa Gástrica/metabolismo , Infecciones por Helicobacter/diagnóstico , Helicobacter pylori/enzimología , Ureasa/metabolismo , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Biomarcadores/metabolismo , Biopsia , Femenino , Mucosa Gástrica/microbiología , Mucosa Gástrica/patología , Infecciones por Helicobacter/patología , Helicobacter pylori/aislamiento & purificación , Hospitales , Humanos , Masculino , Persona de Mediana Edad , Perú , Valor Predictivo de las Pruebas , Estudios Prospectivos , Sensibilidad y Especificidad , Adulto Joven
7.
Rev Gastroenterol Peru ; 37(4): 335-339, 2017.
Artículo en Español | MEDLINE | ID: mdl-29459803

RESUMEN

INTRODUCTION: The hepatopulmonary syndrome (HPS) is a rare complication of liver cirrhosis (LC) which significantly diminishes the quality of life for people who suffer. OBJECTIVES: To determine the prevalence and severity of HPS in patients with CH treated at the Cayetano Heredia (HCH) Hospital in the period from January to December 2015. MATERIALS AND METHODS: Cross-sectional study with sample size needed to determine the point prevalence calculated in 297 patients. RESULTS: The prevalence of HPS in 0.7% and the identified cases were classified as mild and severe SHP. CONCLUSION: The prevalence of HPS is very low in the population of patients with liver cirrhosis treated at the Cayetano Heredia Hospital.


Asunto(s)
Síndrome Hepatopulmonar/epidemiología , Cirrosis Hepática/complicaciones , Adulto , Anciano , Anciano de 80 o más Años , Estudios Transversales , Femenino , Hepatitis Autoinmune/complicaciones , Síndrome Hepatopulmonar/etiología , Hospitales Públicos/estadística & datos numéricos , Humanos , Cirrosis Hepática Alcohólica/complicaciones , Masculino , Persona de Mediana Edad , Perú/epidemiología , Prevalencia , Calidad de Vida , Índice de Severidad de la Enfermedad , Adulto Joven
8.
Rev Gastroenterol Peru ; 35(4): 323-8, 2015.
Artículo en Español | MEDLINE | ID: mdl-26802886

RESUMEN

OBJECTIVE: To validate the score AIMS65 in patients with upper gastrointestinal bleeding, in terms of mortality and rebleeding a 30-day event. MATERIAL AND METHODS: Patients included were those with higher age to 18 years attending the Hospital Nacional Cayetano Heredia during the period May 2013 to December 2014, by upper gastrointestinal bleeding. Data were analyzed using ROC curve (Receiver Operating Characteristic) and the area was obtained under the curve (AUC) to properly qualify the score AIMS65. RESULTS: 209 patients were included, 66.03% were male, with an average age of 58.02 years. The mortality rate was 7.65%, the multiorgan failure the most common cause of death. Plus 3.82% of the patients had recurrent bleeding and 11% required a transfusion of more than 2 units of blood. When analyzing the ROC curve with AIMS65 and mortality score a value of 0.9122 is reported; identifying it as cutoff greater than or equal to 3 value in the score AIMS65 to discriminate patients at high risk of death, likewise the ROC curve was analyzed for recurrence of bleeding with a value of 0.6266 and the need to Transfusion of packed red blood cells over two a value of 0.7421. And it was determined the average hospital stay with a value of 4.8 days, however, no correlation was found with the score AIMS65. CONCLUSIONS: AIMS65 score is a good predictor of mortality, and is useful for predicting the need for transfusion of more than 2 globular packages. However it is not a good predictor for recurrence of bleeding, or hospital stay.


Asunto(s)
Hemorragia Gastrointestinal/diagnóstico , Índice de Severidad de la Enfermedad , Adulto , Anciano , Anciano de 80 o más Años , Transfusión de Eritrocitos/estadística & datos numéricos , Femenino , Estudios de Seguimiento , Hemorragia Gastrointestinal/etiología , Hemorragia Gastrointestinal/mortalidad , Hemorragia Gastrointestinal/terapia , Hospitales Públicos , Humanos , Tiempo de Internación/estadística & datos numéricos , Masculino , Persona de Mediana Edad , Perú , Pronóstico , Estudios Prospectivos , Curva ROC , Recurrencia , Medición de Riesgo
10.
Rev Gastroenterol Peru ; 31(1): 21-5, 2011.
Artículo en Español | MEDLINE | ID: mdl-21544152

RESUMEN

BACKGROUND: Sequential therapy is used as an alternative to growing antibiotic resistance of Helicobacter pylori to the standard triple therapy. Despite the success it had in Europe, we have no information regarding this therapy in our region. OBJECTIVES: To evaluate the eradication rate of Helicobacter pylori using sequential therapy and show its adverse effects. METHODS: We performed a prospective, observational, open descriptive study. 31 patients were evaluated who were treated with sequential therapy in the following way: the first 5 days omeprazole 20 mg and amoxicillin 1 g every 12 hours and following 5 days omeprazole 20 mg, clarithromycin 500 mg and tinidazole 500 mg every 12 hours. After four weeks of treatment, each patient had a C13 urea breath test to check for eradication. RESULTS: 31 patients were included, one patient was excluded from the protocol due to adverse drug react to amoxicillin. Of the remaining 30 patients who completed treatment, 22 (73%) were negative to breath test and 8 (27%) were positive. Of the patients who completed treatment, 10 had minor adverse events to treatment, the main symptoms were epigastralgia and nausea. CONCLUSIONS: Sequential therapy had an eradication rate of 73% which is much lower than that reported in European studies. However, therapy is easily accesible with lower cost and fewer side effects tan standard therapy.


Asunto(s)
Antibacterianos/administración & dosificación , Infecciones por Helicobacter/tratamiento farmacológico , Helicobacter pylori , Adulto , Anciano , Esquema de Medicación , Quimioterapia Combinada , Femenino , Infecciones por Helicobacter/diagnóstico , Hospitales , Humanos , Masculino , Persona de Mediana Edad , Proyectos Piloto , Estudios Prospectivos , Adulto Joven
11.
Rev. gastroenterol. Perú ; 41(1)ene. 2021.
Artículo en Inglés | LILACS-Express | LILACS | ID: biblio-1508562

RESUMEN

Introduction : Irritable bowel syndrome (IBS) is a chronic functional bowel condition with an average world prevalence of 11.2%. Is associated with multiple factors as female sex, young age, stress, anxiety and depression which can have a negative impact on quality of life. IBS in Peru is not investigated at all specially in the Andean region. The objective of this study is to determine the prevalence and associated factors of IBS in an Andean community from Peru using the Rome IV criteria. Materials and methods : Cross-sectional study in a rural community dedicated to livestock and agriculture in Peru at 3,235 meters above sea level. Questionnaires provided by the Rome Foundation as the Rome IV - Diagnostic questionnaire for adults, Irritable Bowel Syndrome - Symptom Severity Scale and Bristol stool scale were used. Results : 130 residents met the inclusion criteria. 46.9% were males with an average age of 54 years old. 11.54% presented red flags and were not included in the analysis. 13.1% were diagnosed with IBS and 52.9% presented constipation as predominant bowel pattern. 52.9% presented a mild course of the disease. In the chi-square analysis, factors as depression, anxiety, female sex, younger age, liquefied petroleum gas exposure for cooking and education achievement were statistically significant associated to IBS. In the logistic regression analysis, anxiety was the unique independent predictor factor with an OR of 9.6 (95% IC: 1.78-51.82). Conclusion : IBS is a prevalent condition in the Andean region and should be managed as a public health issue to improve quality of life.


Introducción : El síndrome del intestino irritable (SII) es una enfermedad intestinal funcional crónica con una prevalencia mundial promedio del 11,2%. Se asocia a múltiples factores como el sexo femenino, la juventud, el estrés, la ansiedad y la depresión que pueden tener un impacto negativo en la calidad de vida. El SII en Perú, no es investigado a profundidad, especialmente en la región andina. El objetivo de este estudio es determinar la prevalencia y factores asociados del SII en una comunidad andina de Perú utilizando los criterios de Roma IV. Materiales y métodos : Estudio transversal en una comunidad rural dedicada a la ganadería y la agricultura en Perú a 3 235 metros sobre el nivel del mar. Se utilizaron cuestionarios proporcionados por la Fundación de Roma como Rome IV - Cuestionario de diagnóstico para adultos, Síndrome del intestino irritable - Escala de gravedad de los síntomas y Escala de heces de Bristol. Resultados : 130 residentes cumplieron los criterios de inclusión. El 46,9% eran varones con una edad media de 54 años. El 11,54% presentó señales de alerta y no fueron incluidos en el análisis. El 13,1% fueron diagnosticados de SII y el 52,9% presentó estreñimiento como patrón intestinal predominante. El 52,9% presentó un curso leve de la enfermedad. En el análisis de chi-cuadrado, factores como depresión, ansiedad, sexo femenino, edad más joven, exposición a gas licuado de petróleo para cocinar y logros educativos fueron estadísticamente significativos asociados con el SII. En el análisis de regresión logística, la ansiedad fue el único factor predictor independiente con una OR de 9,6 (IC del 95%: 1,78-51,82). Conclusión : El SII es una condición prevalente en la región andina y debe ser manejado como un problema de salud pública para mejorar la calidad de vida.

12.
Rev. gastroenterol. Perú ; 39(3)jul. 2019.
Artículo en Español | LILACS-Express | LILACS | ID: biblio-1508549

RESUMEN

Objetivo: Evaluar el éxito de la terapia endoscópica con N-butil-2-cianoacrilato sobre las várices gástricas y determinar las tasas de resangrado y mortalidad. Materiales y métodos: Estudio observacional prospectivo de 47 casos de pacientes con várices gástricas que fueron tratados con N-butil-2-cianoacrilato, utilizando una dilución 1:1 con lipiodol entre febrero de 2013 a marzo de 2017 en un hospital público de nivel III en Lima- Perú. La indicación terapéutica fue hemorragia activa, profilaxis primaria o secundaria. Resultados: De los 47 pacientes, 5 (10,6%) presentaban hemorragia activa, se obtuvo control de la misma en todos los casos, 24 (51,1%) tuvieron estigmas de sangrado reciente durante la endoscopía. Se realizó profilaxis secundaria en 16 (34%) pacientes y profilaxis primaria en 2 (4,7%), 59,6% requirió una sola sesión. El volumen total de cianoacrilato (ml/paciente) promedio fue 1,28 ± 0,44. Se aplicó una sola inyección por sesión en el 87,2% de los pacientes. El hallazgo endoscópico fue GOV-2 en el 78,7% de los casos, IGV-1 en el 12,8% y GOV-1 en el 8,5%. Siete pacientes (14,8%) presentaron resangrado tardío, con nueva terapia exitosa en 6 de ellos, uno fallece por fracaso de la terapia. Seis (12,76%) pacientes fallecen en total, cinco (83,3%) por otras causas. Se realizó 18 meses de seguimiento. No se reportaron eventos adversos relacionados con la terapia. Se constata obturación en 28 (59,5%) pacientes. Conclusiones: El manejo endoscópico de várices gástricas con cianoacrilato es un tratamiento seguro y eficaz, con baja tasa de recurrencia y mortalidad.


Objective: To evaluate the therapeutic success of endoscopic therapy with N-butyl-2-cyanoacrylate and to determine the rebleeding and mortality rates. Materials and methods: Prospective analytical observational study of 47 cases of patients with gastric varices who were treated with N-butyl-2-cyanoacrylate, using a 1: 1 mixture with lipiodol between 2013 and 2017 in a level III public hospital in Lima - Peru. The therapeutic indication was active hemorrhage, primary or secondary prophylaxis. Results: Of the 47 patients, 5 (10.6%) had active hemorrhage, control was obtained in all cases, 24 (51.1%) had stigmas of recent bleeding during endoscopy. Secondary prophylaxis was performed in 16 (34%) patients and primary prophylaxis in 2 (4.7%). 59.6% required a single session with a total volume of cyanoacrylate (ml / patient) of 1.28 ± 0.44. The endoscopic finding was GOV-2 in 78.7% of the cases, IGV-1 in 12.8% and GOV-1 in 8.5%. Seven patients (14.8%) presented late rebleeding, with successful new therapy in 6 of them, one dying due to therapy failure. Of the six (12.76%) patients who died in total, 5 (83.3%) were due to other causes. No adverse events related to the therapy were reported. No adverse events were reported. Variceal obturation was observed in 28 (59.5%) patients. Conclusions: Endoscopic management of gastric varices with cyanoacrylate is a safe and effective treatment, with low recurrence and mortality rates.

13.
Rev. gastroenterol. Perú ; 39(3)jul. 2019.
Artículo en Español | LILACS-Express | LILACS | ID: biblio-1508547

RESUMEN

En hemorragia digestiva baja (HDB) es muy importante estratificar el riesgo de la misma para brindar un manejo adecuado. Objetivo: Identificar los factores predictores de mortalidad y severidad en pacientes con HDB (definida como: requerimiento de unidad de cuidados críticos, control de hemorragia en sala de operaciones, estancia prolongada mayor a 9 días, resangrado, reingreso, o politransfusión más de 5 paquetes globulares). Materiales y métodos: Es un estudio observacional analítico de cohorte prospectivo, realizado entre junio del 2016 y abril del 2018 en un hospital de nivel III. Se determinó los factores predictores de mortalidad y severidad. Se evalúo la sobrevida hasta los 30 días Resultados: Se incluyó un total de 98 pacientes de los cuales 13 pacientes (13,3%) fallecieron y 56 (57,1%) cumplen criterios de severidad. El factor predictor independiente de mortalidad fue escala de Glasgow menor a 15 y los factores independientes de severidad fueron un valor de albúmina menor a 2,8 g/dl y la presión arterial sistólica menor a 100 mmhg. Conclusiones: La frecuencia de mortalidad y HDB severa es alta en nuestro estudio. La presión arterial sistólica, la escala de Glasgow y la albúmina sérica son evaluaciones que pueden permitirnos predecir durante la primera evaluación en emergencia el riesgo de severidad y mortalidad de un paciente con HDB.


In lower gastrointestinal bleeding (LGIB), it is very important to stratify the risk of LGIB for a proper management. Objective: Identity the independent risk factors to mortality and severity (require critical care, prolonged hospitalization, reebleding, re hospitalization, politrasfusion, surgery for bleeding control) in LGIB. Materials and methods: It is an analytic prospective cohort study, performed between June 2016 and April 2018 in a tertiary care hospital. Independent factors were determined using binomial logistic regression. Results: A total of 98 patients were included, of which 13 patients (13,3%) died, and 56 (57,1%) met severity criteria. The independent risk factor for mortality was Glasgow scale under 15, and for severe bleeding were: Systolic blood pressure under 100 mm Hg, albumin lower than 2,8 g/dL. Conclusions: The frequency of mortality and severe LGIB is high in our population, the principal risk factors were systolic blood pressure under than 100 mm Hg, Glasgow score lower than 15, albumin lower than 2,8 g/dL. Identifying these associated factors would improve the management of LGB in the emergency room.

14.
Rev. gastroenterol. Perú ; 38(1): 22-28, jan.-mar. 2018. ilus, tab
Artículo en Español | LILACS | ID: biblio-1014053

RESUMEN

Antecedentes: Habitualmente se utilizan los predictores propuestos por la Sociedad Americana de Endoscopía Gastrointestinal (ASGE) para predecir la presencia y manejo de coledocolitiasis. Objetivo: Evaluar el rendimiento y precisión de los predictores de coledocolitiasis propuestos por la ASGE. Materiales y métodos: Estudio prospectivo y longitudinal realizado en un hospital de tercer nivel desde enero del 2015 hasta junio del 2017. Se incluyeron a todos los pacientes con probabilidad alta e intermedia de coledocolitiasis y que fueron sometidos a colangiopancreatografía retrógrada endoscópica (CPRE) según los criterios propuestos por la ASGE. Resultados: Se analizó un total de 246 pacientes con sospecha de coledocolitiasis. De los 228 pacientes con criterios de alta probabilidad, 144 (63,2% = rendimiento) tenían coledocolitiasis en la CPRE con una precisión de 62% (sensibilidad: 94,1% y especificidad: 9,7%). Entre los 18 pacientes con criterios de probabilidad intermedia: 9 (50% = rendimiento) tenían coledocolitiasis con una precisión de 38% (sensibilidad: 5,9% y especificidad: 90,3%). En el análisis multivariado la presencia de cálculo en el colédoco por ecografía (OR: 1,937; IC 95% 1,048- 3,580; p=0,035) y la edad mayor de 55 años (OR: 2,121; IC 95% 1,101-4,088; p=0,025) fueron los predictores más fuertes para coledocolitiasis. Conclusiones: La aplicación de los criterios de la ASGE para predecir probabilidad de coledocolitiasis, en nuestra población tiene un rendimiento mayor del 50%; sin embargo, se necesita mejorar estos parámetros para evitar una realización innecesaria de CPRE.


Background: The predictors proposed by the American Society of Gastrointestinal Endoscopy (ASGE) are commonly used to predict the presence and management of choledocholithiasis. Objective: To evaluate the performance and precision of the predictors of choledocholithiasis proposed by ASGE. Materials and methods: Prospective and longitudinal study performed at a third level hospital during January 2015 to June 2017. All patients with high and intermediate probability of choledocholithiasis who underwent endoscopic retrograde cholangiopancreatography (ERCP) were included according to the criteria proposed by the ASGE. Results: A total of 246 patients with suspected choledocholithiasis were analyzed. Of the 228 patients with high probability criteria 144 (63.2% = performance) had choledocholithiasis in ERCP with an accuracy of 62% (sensitivity: 94.1% and specificity: 9.7%). Among the 18 patients with intermediate probability criteria, 9 (50% = performance) had choledocholithiasis with an accuracy of 38% (sensitivity: 5.9% and specificity: 90.3%). In the multivariate analysis, the presence of stone in the bile duct by ultrasonography (OR: 1.937, 95% CI 1.048-3.580, p=0.035) and age 55 and over (OR: 2.121, 95% CI, 1.101-4.088, p=0.025) were the strongest predictors for choledocholithiasis. Conclusions: The application of the criteria of the ASGE to predict the probability of choledocholithiasis, in our population has a performance greater than 50%, however, it is necessary to improve these parameters to avoid an unnecessary performance of ERCP.


Asunto(s)
Adulto , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Masculino , Persona de Mediana Edad , Coledocolitiasis/diagnóstico , Perú , Sociedades Médicas , Análisis Multivariante , Estudios Prospectivos , Estudios Longitudinales , Endoscopía Gastrointestinal , Ultrasonografía , Sensibilidad y Especificidad , Colangiopancreatografia Retrógrada Endoscópica , Toma de Decisiones Clínicas , Hospitales Públicos
15.
Rev. gastroenterol. Perú ; 37(1): 53-57, ene.-mar. 2017. ilus, tab
Artículo en Español | LILACS | ID: biblio-991224

RESUMEN

Objetivos: Validar un test rápido de la ureasa (TRU) en el Hospital Cayetano Heredia (HCH) de Lima, Perú Materiales y métodos: Estudio observacional prospectivo. Se incluyó 181 pacientes mayores de 18 años de edad con síntomas dispépticos, que fueron sometidos a endoscopía digestiva alta en el Servicio de Gastroenterología del HCH y que no hubiesen recibido durante las últimas cuatro semanas inhibidores de la bomba de protones (IBPs), bismuto o antibióticos. Se tomó dos biopsias de antro una para hacer el TRU (Sensibacter pylori test®) y otra para anatomía patológica con el fin de determinar la presencia de la infección por H. pylori por ambos métodos. Finalmente se comparó el resultado de la anatomía patológica (patrón de oro) con el de TRU. Resultados: Se evaluó 181 pacientes, la edad promedio fue 52,8±13,5 años. La sensibilidad, especificidad, valor predictivo negativo (VPN), valor predictivo positivo (VPP) a los 20 minutos fueron de 86,8%, 98,5%, 81,5% y 99% y a las 24 horas 97,3%, 99,5%, 95,7% y 99,1% respectivamente. Conclusión: El TRU es un test confiable, accesible y de fácil aplicación para hacer el diagnóstico de la infección por H. pylori.


Objective: To validate a rapid urease test (RUT) in Cayetano Heredia Hospital (HCH) in Lima, Peru. Materials and methods: This is a prospective observational study that included 181 patients over 18 years old with dyspeptic symptoms. All of them underwent upper gastrointestinal endoscopy at the Department of Gastroenterology at HCH. They had not received, during the last four weeks, proton pump inhibitors (PPIs), bismuth or antibiotics. Two biopsies of antrum were taken, one to perform the TRU (Sensibacter pylori test®) and the other one for pathology, in order to determine by both methods the presence of H. pylori infection. TRU’s results were compared with pathology´s (gold standard). Results: 181 patients, average age 52.8±13.5 years, were evaluated. The sensitivity, specificity, negative predictive value (NPV), positive predictive value (PPV) at 20 minutes were 86.8%, 98.5%, 81.5% and 99% and at 24 hours 97.3%, 99.5%, 95.7% y 99.1% respectively. Conclusion: The rapid urease test is a reliable, accessible and easy to apply test for the diagnosis of H. pylori infection.


Asunto(s)
Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Masculino , Persona de Mediana Edad , Adulto Joven , Ureasa/metabolismo , Helicobacter pylori/enzimología , Infecciones por Helicobacter/diagnóstico , Mucosa Gástrica/metabolismo , Perú , Biopsia , Biomarcadores/metabolismo , Valor Predictivo de las Pruebas , Estudios Prospectivos , Helicobacter pylori/aislamiento & purificación , Infecciones por Helicobacter/patología , Sensibilidad y Especificidad , Mucosa Gástrica/microbiología , Mucosa Gástrica/patología , Hospitales
16.
Rev. gastroenterol. Perú ; 37(4): 335-339, oct.-dic. 2017. ilus, tab
Artículo en Español | LILACS | ID: biblio-991276

RESUMEN

Introducción: El sindrome hepatopulmonar (SHP) es una complicación poco frecuente de la cirrosis hepática (CH) que disminuye considerablemente la calidad de vida de las personas que la padecen. Objetivos: Determinar la prevalencia y severidad del SHP en los pacientes con CH atendidos en el Hospital Nacional Cayetano Heredia (HCH) en el periodo comprendido entre enero a diciembre del 2015. Material y métodos: Estudio transversal, con tamaño de muestra necesario para determinar la prevalencia puntual calculado en 297 pacientes. Resultados: La prevalencia del SHP fue de 0,7% y los casos identificados se clasificaron como SHP leve y severo. Conclusión: La prevalencia del SHP es muy baja en la población de pacientes con cirrosis hepática atendidos en el Hospital Nacional Cayetano Heredia


Introduction: The hepatopulmonary syndrome (HPS) is a rare complication of liver cirrhosis (LC) which significantly diminishes the quality of life for people who suffer. Objectives: To determine the prevalence and severity of HPS in patients with CH treated at the Cayetano Heredia (HCH) Hospital in the period from January to December 2015. Materials and methods: Cross-sectional study with sample size needed to determine the point prevalence calculated in 297 patients. Results: The prevalence of HPS in 0.7% and the identified cases were classified as mild and severe SHP. Conclusion: The prevalence of HPS is very low in the population of patients with liver cirrhosis treated at the Cayetano Heredia Hospital


Asunto(s)
Adulto , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Masculino , Persona de Mediana Edad , Adulto Joven , Síndrome Hepatopulmonar/epidemiología , Cirrosis Hepática/complicaciones , Perú/epidemiología , Calidad de Vida , Índice de Severidad de la Enfermedad , Prevalencia , Estudios Transversales , Hepatitis Autoinmune/complicaciones , Síndrome Hepatopulmonar/etiología , Hospitales Públicos/estadística & datos numéricos , Cirrosis Hepática Alcohólica/complicaciones
17.
Rev. méd. hered ; 26(1): 47-50, ene. 2015.
Artículo en Español | LILACS, LIPECS | ID: lil-744170

RESUMEN

Náusea y vómitos persistentes, como síntoma principal de presentación de la enfermedad, es raro en hipertiroidismo. Se reporta el caso de una mujer de 76 años, que acudió por presentar náusea, vómitos persistentes y dolor abdominal. Al ingreso, se halló taquicardia, fiebre, edema de miembros inferiores, bocio difuso y abdomen doloroso a la palpación. Se realizó ecografía abdominal, endoscopía alta y tomografía abdominal que no mostraron alteraciones significativas. Inicialmente, se plantearon los diagnósticos de infección urinaria complicada y luego colangitis infecciosa; sin embargo, el uso de antibióticos y antieméticos no mejoraron el cuadro de vómitos. Finalmente, se determinaron hormonas tiroideas resultando TSH suprimido y T4 libre y T3 total elevados. Los vómitos cesaron con la administración de propanolol y tiamazol. La paciente fue dada de alta sin molestias. No se conoce el mecanismo fisiopatológico; sin embargo, el uso de beta-bloqueadores y tionamidas resuelve rápidamente el cuadro. (AU)


Nausea and vomiting, as the main presenting symptoms, are rare manifestations of hyperthyroidism. We report the case of a-76-year old woman complaining of nausea, vomiting and abdominal pain. The physical examination at admission revealed tachycardia, fever, edema, diffuse goiter, and a painful abdomen. An extensive work-up was carried-out, that included abdominal ultrasound, upper endoscopy and abdominal CT-scan that were unrevealing. The initial diagnoses were complicated urine tract infection and cholangitis; however, the use of antibiotics and antiemetics did not resolve the symptoms. Finally, thyroid hormone dosage showed suppressed TSH and high levels of free thyroxine and triiodothyronine. Vomiting ceased soon after the administration of propranolol and methimazole. The patient was discharged without complaints. The pathogenesis of vomiting in patients with hyperthyroidism is unknown, but treatment with beta-blockers and thionamides quickly resolved the symptoms. (AU)


Asunto(s)
Humanos , Femenino , Anciano , Glándula Tiroides , Vómitos , Tirotoxicosis , Hipertiroidismo
19.
Rev. gastroenterol. Perú ; 31(1): 21-25, ene.-mar. 2011. tab, graf
Artículo en Español | LILACS, LIPECS | ID: lil-587342

RESUMEN

INTRODUCCIÓN: La terapia secuencial nace como una alternativa a la creciente resistencia antibiótica del Helicobacter pylori (HP) a la terapia triple (estándar). A pesar de los resultados satisfactorios que ha tenido en Europa, en nuestro medio no tenemos referencia de un estudio al respecto. OBJETIVOS: Evaluar la tasa de erradicación del Helicobacter pylori empleando la terapia secuencial y evidenciar sus efectos adversos. METODOLOGÍA: Se realiza un estudio prospectivo, observacional, descriptivo, abierto. Se evaluaron 31 pacientes que recibieron tratamiento con terapia secuencial de la siguiente forma, los 5 primeros días omeprazol 20 mg y amoxicilina de 1 g cada 12 horas y los 5 días siguientes omeprazol 20 mg, claritromicina 500 mg y tinidazol de 500 mg cada 12 horas. A las 4 semanas de terminado el tratamiento se le realizó a cada paciente una prueba de aliento con carbono 13 para comprobar la erradicación del HP. RESULTADOS: Se incluyeron a 31 pacientes, un paciente fue excluido del protocolo por presentar RAM a la amoxicilina. De los 30 pacientes restantes que completaron el tratamiento, 22 (73%) resultaron negativos en la prueba del aliento y 8 (27%) resultaron positivos. De los pacientes que completaron el tratamiento, 10 presentaron eventos adversos menores al tratamiento, principalmente epigastralgia y náuseas. CONCLUSIONES: La terapia secuencial tuvo una tasa de erradicación del 73% la cual es mucho menor a la reportada en los estudios europeos. Sin embargo, es una terapia de fácil acceso, de menor costo y con menores efectos colaterales.


BACKGROUND: Sequential therapy is used as an alternative to growing antibiotic resistance of Helicobacter pylori to the standard triple therapy. Despite the success it had in Europe, we have no information regarding this therapy in our region. OBJECTIVES: To evaluate the eradication rate of Helicobacter pylori using sequential therapy and show its adverse effects. METHODS: We performed a prospective, observational, open descriptive study. 31 patients were evaluated who were treated with sequential therapy in the following way: the first 5 days omeprazole 20 mg and amoxicillin 1 g every 12 hours and following 5 days omeprazole 20 mg, clarithromycin 500 mg and tinidazole 500 mg every 12 hours. After four weeks of treatment, each patient had a C13 urea breath test to check for eradication.RESULTS: 31 patients were included, one patient was excluded from the protocol due to adverse drug react to amoxicillin. Of the remaining 30 patients who completed treatment, 22 (73%) were negative to breath test and 8 (27%) were positive. Of the patients who completed treatment, 10 had minor adverse events to treatment, the main symptoms were epigastralgia and nausea. CONCLUSIONS: Sequential therapy had an eradication rate of 73% which is much lower than that reported in European studies. However, therapy is easily accesible with lower cost and fewer side effects tan standard therapy.


Asunto(s)
Humanos , Masculino , Femenino , Adolescente , Adulto , Persona de Mediana Edad , Amoxicilina/uso terapéutico , Claritromicina/uso terapéutico , Helicobacter pylori , Infecciones por Helicobacter/terapia , Omeprazol/uso terapéutico , Tinidazol/uso terapéutico , Epidemiología Descriptiva , Estudios Prospectivos , Estudios Observacionales como Asunto , Perú
20.
Rev Gastroenterol Peru ; 25(1): 23-41, 2005.
Artículo en Español | MEDLINE | ID: mdl-15818420

RESUMEN

BACKGROUND: Helicobacter pylori (Hp) infection has been associated with the presence of duodenal ulcer, gastric ulcer and chronic active gastritis. It is also speculated that Hp may have a major role in gastric cancer development. Due to rising antibiotic resistance, probably lack of compliance and the expense of the currently used antimicrobial regimens, it's important to develop efficacious, short-duration and low cost therapies, especially for the treatment of low-income populations from underdeveloped countries. The goal of the present study is to asses the efficacy of two ultrashort antibiotic schemes against Hp infection. METHODS: Patients with diagnosis of Hp infection, found in antral gastric biopsies, were included. They were randomly assigned to receive one of the following therapeutic schemes: tetracycline 500 mg qid, furazolidone 100 mg qid and colloidal bismuth subcitrate 120 mg qid for 3 days (Scheme I) or 4 days (Scheme II). Patients were instructed to come back for follow-up at least 8 weeks after starting medication. At the control visit, an upper endoscopy was performed and an average of 3 antral biopsies was taken. Biopsies were stained with hematoxylin-eosin for histological assessment and with Warthin-Starry silver staining for Hp diagnosis. A single experienced pathologist read all biopsies. In both, the initial biopsy and the control one, we evaluated: presence of Hp; presence, depth and grade of chronic gastritis; presence and grade of inflammatory activity; presence, grade and extent of mucinous damage; presence of glandular atrophy, intestinal metaplasia and lymphoid follicles. We also evaluated dyspeptic symptoms prior and after the treatment, and the presence of adverse events. RESULTS: 80 patients were enrolled, 2 were excluded because of intense nausea and vomits, 4 patients didn't follow the indications properly and 8 patients couldn't be contacted for the control visit. From the remaining 66 patients, 32 were assigned to Scheme I and 34 to Scheme II, both groups were comparable. Eradication rate was 68.8% (22/32) (CI = 52.1% - 82.7%) for Scheme I and 88.2% (30/34) (CI = 74.9% - 96.2%), significant higher, for Scheme II. There was decrease of dyspeptic symptoms and significant improvement of the histological pattern for both groups, except for presence of chronic gastritis, intestinal metaplasia, glandular atrophy and lymphoid follicles. Hp eradication was associated with significant symptoms decrease, normal endoscopy raising and improvement of all the histological parameters, except for presence of intestinal metaplasia and glandular atrophy. Treatment was well tolerated, 57.6% of the patients reported only mild adverse events, nausea was the most frequent (19.7%) and there was no difference between schemes. CONCLUSIONS: The triple ultrashort duration scheme including tetracycline, furazolidone and bismuth for 4 days is efficacious against Hp, with a high eradication rate (88.2%). The Hp disappearance is followed by improvement in every histological parameter that we evaluated, except for glandular atrophy and intestinal metaplasia; and it's also accompanied by a decrease in dyspeptic symptoms.


Asunto(s)
Antibacterianos/uso terapéutico , Antiinfecciosos/uso terapéutico , Furazolidona/uso terapéutico , Infecciones por Helicobacter/complicaciones , Infecciones por Helicobacter/tratamiento farmacológico , Helicobacter pylori , Compuestos Organometálicos/uso terapéutico , Úlcera Péptica/complicaciones , Úlcera Péptica/tratamiento farmacológico , Tetraciclina/uso terapéutico , Adolescente , Adulto , Anciano , Esquema de Medicación , Quimioterapia Combinada , Femenino , Hospitales , Humanos , Masculino , Persona de Mediana Edad , Estudios Prospectivos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA